サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1428137

グランドマル発作治療の世界市場レポート 2024年

Grand Mal Seizure Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
グランドマル発作治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

グランドマル発作治療の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には5.2%の年間複合成長率（CAGR）で24億8,000万米ドルに成長すると予想されます。予測期間で予想される成長は、遺伝子調査の進歩と精密医療の導入、遠隔患者ケアのための遠隔医療の統合、治療へのアクセスを高める規制の修正、脳画像技術の進歩、応用など、さまざまな要因に関連している可能性があります。総合的な治療アプローチのこと。この予測期間に予想される主要動向には、てんかんに対する意識の向上、患者中心のケアモデルの確立、発作遺伝学への調査の重点化、地域社会の支援ネットワークの開発、非薬物治療アプローチの探求を目的とした世界の権利擁護活動が含まれます。これらの動向は、予測期間におけるグランドマル発作の管理と治療の進歩に影響を与え、貢献する可能性があります。

グランドマル発作治療市場の予想される成長は、てんかんの有病率の高さによって大きく影響されます。てんかんは、繰り返し発作を特徴とする神経疾患で、特に激しく激しいグランドマル発作として現れることがよくあります。世界中でてんかんの有病率が上昇していることは、特にグランドマル発作に対処するために調整された治療選択肢の改善が差し迫った必要性を浮き彫りにしています。2023年2月の時点で、世界保健機関は、世界中で約5,000万人がてんかんに苦しんでおり、てんかんは世界で最も蔓延している神経疾患の1つであると報告しました。年間約500万人の診断率を誇るてんかんの有病率は、グランドマル発作治療市場の成長を促進する主要原動力となっています。

グランドマル発作治療市場の成長軌道は、個別化医療の採用の増加によってさらに推進されています。革新的な医療アプローチである個別化医療は、個々の患者の固有の特性に合わせて治療を調整します。 グランドマル発作治療のコンテキストでは、個別化医療には、患者固有の特性に基づいて、より効果的で忍容性が高いと思われる薬剤を選択するなど、介入をカスタマイズするために個人の遺伝的と分子的プロファイルを分析することが含まれます。この精度重視のアプローチは、各患者への悪影響を最小限に抑えながら発作制御を強化する可能性を秘めています。 2022年、食品医薬品局の医薬品評価研究センター（CDER）は37の新しい分子実体（NME）を承認し、そのうち約34％、12のNMEが個別化医療連合（PMC）によって個別化医療として分類されました。この個別化医療の大幅な導入は、グランドマル発作治療市場の成長を促進する重要な要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界のグランドマル発作治療市場の促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界のグランドマル発作治療市場規模実績と成長、2018～2023年
  • 世界のグランドマル発作治療市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界のグランドマル発作治療市場、タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • バルビツール酸塩
  • ヒダントイン
  • フェニルトリアジン
  • イミノスチルベン
  • ベンゾジアゼピン系
  • 脂肪族カルボン酸
  • その他
  • 世界のグランドマル発作治療市場、診断別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 磁気共鳴画像法（MRI）
  • 脳波（EEG）
  • 血液検査
  • コンピュータ断層撮影（CT）
  • その他
  • 世界のグランドマル発作治療市場、治療別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 抗てんかん薬
  • 手術
  • 迷走神経刺激
  • ケトジェニックダイエット
  • その他
  • 世界のグランドマル発作治療市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 学術研究センター
  • 神経センター
  • 病院
  • その他

第7章 地域と国の分析

  • 世界のグランドマル発作治療市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
  • 世界のグランドマル発作治療市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • グランドマル発作治療市場の競合情勢
  • グランドマル発作治療市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson Inc.
    • Novartis AG
    • Sanofi SA
    • GlaxoSmithKline PLC

第31章 その他の大手と革新的な企業

  • Takeda Pharmaceuticals Inc.
  • Mylan NV
  • UCB Celltech Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Limited
  • Lupin Pharmaceuticals Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Inc.
  • Apotex Inc.
  • Hikma Pharmaceuticals PLC
  • Alkem Laboratories Ltd.
  • Jubilant Life Sciences Limited
  • Torrent Pharmaceuticals Ltd.
  • Zydus Cadila

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

目次
Product Code: r13981

Treatment for grand mal seizures involves medical interventions and management strategies aimed at controlling or minimizing the impact of tonic-clonic seizures on an individual's life. The goal is to prevent or reduce the frequency, duration, and intensity of seizures while mitigating potential medication side effects.

Key categories of grand mal seizure treatments include barbiturates, hydantoin, phenyltriazine, iminostilbenes, benzodiazepines, aliphatic carboxylic acids, and other medication classes. Barbiturates function as central nervous system depressants, serving as sedatives, hypnotics, and anticonvulsants. Diagnosis methods may encompass magnetic resonance imaging (MRI), electroencephalogram (EEG), blood tests, computed tomography (CT), and other diagnostic procedures. Treatment options include antiepileptic drugs, surgical interventions, vagus nerve stimulation, ketogenic diet, among others. These treatments cater to various end-users, including academic and research centers, neurological facilities, hospitals, and other healthcare providers.

The grand mal seizure treatment market research report is one of a series of new reports from The Business Research Company that provides grand mal seizure treatment market statistics, including grand mal seizure treatment industry global market size, regional shares, competitors with a grand mal seizure treatment market share, detailed grand mal seizure treatment market segments, market trends and opportunities, and any further data you may need to thrive in the grand mal seizure treatment industry. This grand mal seizure treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The grand mal seizure treatment market size has grown strongly in recent years. It will grow from $1.91 billion in 2023 to $2.02 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth observed in the historical period can be credited to several factors such as advancements in neurological understanding, medical progress, the development of medications targeted at seizures, the establishment of seizure classification systems, and advocacy efforts in legal and social domains. These combined factors significantly contributed to the evolution and improvements in the management and treatment of grand mal seizures during the historical period.

The grand mal seizure treatment market size is expected to see strong growth in the next few years. It will grow to $2.48 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. Anticipated growth in the forecast period can be linked to various factors, including advancements in genetic research and the adoption of precision medicine, the integration of telemedicine for remote patient care, regulatory modifications enhancing accessibility to treatments, advancements in brain imaging techniques, and the application of holistic treatment approaches. Key trends expected in this forecasted period encompass global advocacy initiatives aimed at raising awareness about epilepsy, the establishment of patient-centered care models, increased research focus on seizure genetics, the development of community support networks, and the exploration of non-pharmacological treatment approaches. These trends are likely to influence and contribute to the progression of managing and treating grand mal seizures in the forecasted period.

The anticipated growth of the grand mal seizure treatment market is strongly influenced by the high prevalence of epilepsy. Epilepsy, a neurological disorder characterized by recurring seizures, often manifests as grand mal seizures, which are particularly intense and violent. The rising prevalence of epilepsy worldwide underscores the pressing need for improved treatment options, specifically tailored to address grand mal seizures. As of February 2023, the World Health Organization reported that approximately 50 million people globally were grappling with epilepsy, marking it as one of the most prevalent neurological conditions globally. With an annual diagnosis rate of about 5 million people, the escalating prevalence of epilepsy serves as a primary driver fueling the growth of the grand mal seizure treatment market.

The growth trajectory of the grand mal seizure treatment market is further propelled by the increasing adoption of personalized medicines. Personalized medicine, an innovative healthcare approach, tailors medical treatments to the unique characteristics of individual patients. In the context of grand mal seizure treatment, personalized medicine involves analyzing an individual's genetic and molecular profile to customize interventions, such as selecting medications that are likely to be more effective and better tolerated based on the patient's unique characteristics. This precision-driven approach holds the potential to enhance seizure control while minimizing adverse effects for each patient. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), and approximately 34% of these, amounting to 12 NMEs, were classified as personalized medicines by the Personalized Medicine Coalition (PMC). This significant adoption of personalized medicine practices is a key factor driving the growth of the grand mal seizure treatment market.

Major players in the grand mal seizure treatment market are strategically introducing new products, with a focus on anti-epilepsy medications, to gain a competitive advantage. Anti-epilepsy medications, also known as antiepileptic drugs (AEDs) or anticonvulsants, form a crucial class of pharmaceuticals designed to manage and treat epileptic seizures and related disorders. An illustrative example is Zydus Lifesciences Limited, an India-based pharmaceutical company, which, in January 2023, launched Topiramate extended-release capsules in the U.S. market. Zydus achieved the distinction of being the first company to receive final approval and introduce the product in strengths of USP 25 mg, 50 mg, and 100 mg. These capsules are indicated for epilepsy treatment, specifically as initial monotherapy for patients aged six and older with partial-onset or primary generalized tonic-clonic seizures. Additionally, they are approved for migraine prophylaxis in patients aged 12 and older, marking a significant contribution to the evolving landscape of grand mal seizure treatment.

Major companies actively participating in the grand mal seizure treatment market are advancing product development by introducing advanced offerings, particularly small molecule anticonvulsants for refractory focal onset seizures. Small molecule anticonvulsants, characterized by low molecular weight compounds, are instrumental in preventing or controlling seizures in individuals with epilepsy or other neurological disorders. An exemplar in this domain is Xenon Pharmaceuticals Inc., a Canada-based biopharmaceutical company, which launched the Phase 3 program for XEN1101 in November 2022 with the initiation of the X-TOLE2 clinical trial. This trial aims to investigate the use of XEN1101 as an adjunctive treatment for adult patients with focal epilepsy. XEN1101, a differentiated Kv7 potassium channel opener, has garnered positive Phase 2b clinical data, supporting its progression through late-stage clinical development toward commercialization. The introduction of advanced small molecule anticonvulsants represents a strategic move to establish a competitive edge in the dynamic grand mal seizure treatment market.

In March 2022, UCB, a biopharmaceutical company headquartered in Belgium, completed the acquisition of Zogenix for an estimated $1.9 billion. This strategic acquisition is poised to enable UCB to broaden its portfolio within emerging therapy segments and expand its presence in new geographical regions. Zogenix, based in the United States, specializes in the development and production of medications and therapies targeted at treating grand mal seizures. This acquisition signifies UCB's commitment to advancing its offerings in the treatment landscape for grand mal seizures and expanding its global footprint in the pharmaceutical industry.

Major companies operating in the grand mal seizure treatment market report are Pfizer Inc., Johnson & Johnson Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceuticals Inc., Mylan N.V., UCB Celltech Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Lupin Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Cipla Inc., Apotex Inc., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Jubilant Life Sciences Limited, Torrent Pharmaceuticals Ltd., Zydus Cadila, Strides Pharma Science Limited, Glenmark Pharmaceuticals Ltd., Wockhardt Ltd., Macleods Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Limited, Indoco Remedies Limited, Spectrum Chemical Mfg. Corp.

North America was the largest region in the grand mal seizure treatment market in 2023. The regions covered in the grand mal seizure treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the grand mal seizure treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The grand mal seizure treatment market consists of revenues earned by entities by providing deep brain stimulation, complementary therapies, and surgical procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The grand mal seizure treatment market also includes sales of brivaracetam, carbamazepine, clobazam, and felbamate. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Grand Mal Seizure Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on grand mal seizure treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for grand mal seizure treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The grand mal seizure treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Barbiturates; Hydantoin; Phenyltriazine; Iminostilbenes; Benzodiazepines; Aliphatic Carboxylic Acids; Other Types
  • 2) By Diagnosis: Magnetic Resonance Imaging (MRI); Electroencephalogram (EEG); Blood Tests; Computed Tomography (CT); Other Diagnosis
  • 3) By Treatment: Antiepileptic Drugs; Surgery; Vagus Nerve Stimulation; Ketogenic Diet; Other Treatments
  • 4) By End Users: Academic And Research Centers; Neurological Centers; Hospitals; Other End Users
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Inc.; Novartis AG; Sanofi S.A.; GlaxoSmithKline PLC
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Grand Mal Seizure Treatment Market Characteristics

3. Grand Mal Seizure Treatment Market Trends And Strategies

4. Grand Mal Seizure Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Grand Mal Seizure Treatment Market Size and Growth

  • 5.1. Global Grand Mal Seizure Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Grand Mal Seizure Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Grand Mal Seizure Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Grand Mal Seizure Treatment Market Segmentation

  • 6.1. Global Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Barbiturates
  • Hydantoin
  • Phenyltriazine
  • Iminostilbenes
  • Benzodiazepines
  • Aliphatic Carboxylic Acids
  • Other Types
  • 6.2. Global Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Magnetic Resonance Imaging (MRI)
  • Electroencephalogram (EEG)
  • Blood Tests
  • Computed Tomography (CT)
  • Other Diagnosis
  • 6.3. Global Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Antiepileptic Drugs
  • Surgery
  • Vagus Nerve Stimulation
  • Ketogenic Diet
  • Other Treatments
  • 6.4. Global Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Academic And Research Centers
  • Neurological Centers
  • Hospitals
  • Other End Users

7. Grand Mal Seizure Treatment Market Regional And Country Analysis

  • 7.1. Global Grand Mal Seizure Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Grand Mal Seizure Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Grand Mal Seizure Treatment Market

  • 8.1. Asia-Pacific Grand Mal Seizure Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Grand Mal Seizure Treatment Market

  • 9.1. China Grand Mal Seizure Treatment Market Overview
  • 9.2. China Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Grand Mal Seizure Treatment Market

  • 10.1. India Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Grand Mal Seizure Treatment Market

  • 11.1. Japan Grand Mal Seizure Treatment Market Overview
  • 11.2. Japan Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Grand Mal Seizure Treatment Market

  • 12.1. Australia Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Grand Mal Seizure Treatment Market

  • 13.1. Indonesia Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Grand Mal Seizure Treatment Market

  • 14.1. South Korea Grand Mal Seizure Treatment Market Overview
  • 14.2. South Korea Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Grand Mal Seizure Treatment Market

  • 15.1. Western Europe Grand Mal Seizure Treatment Market Overview
  • 15.2. Western Europe Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Grand Mal Seizure Treatment Market

  • 16.1. UK Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Grand Mal Seizure Treatment Market

  • 17.1. Germany Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Grand Mal Seizure Treatment Market

  • 18.1. France Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Grand Mal Seizure Treatment Market

  • 19.1. Italy Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Grand Mal Seizure Treatment Market

  • 20.1. Spain Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Grand Mal Seizure Treatment Market

  • 21.1. Eastern Europe Grand Mal Seizure Treatment Market Overview
  • 21.2. Eastern Europe Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Grand Mal Seizure Treatment Market

  • 22.1. Russia Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Grand Mal Seizure Treatment Market

  • 23.1. North America Grand Mal Seizure Treatment Market Overview
  • 23.2. North America Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Grand Mal Seizure Treatment Market

  • 24.1. USA Grand Mal Seizure Treatment Market Overview
  • 24.2. USA Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Grand Mal Seizure Treatment Market

  • 25.1. Canada Grand Mal Seizure Treatment Market Overview
  • 25.2. Canada Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Grand Mal Seizure Treatment Market

  • 26.1. South America Grand Mal Seizure Treatment Market Overview
  • 26.2. South America Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Grand Mal Seizure Treatment Market

  • 27.1. Brazil Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Grand Mal Seizure Treatment Market

  • 28.1. Middle East Grand Mal Seizure Treatment Market Overview
  • 28.2. Middle East Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Grand Mal Seizure Treatment Market

  • 29.1. Africa Grand Mal Seizure Treatment Market Overview
  • 29.2. Africa Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Grand Mal Seizure Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Grand Mal Seizure Treatment Market Competitive Landscape
  • 30.2. Grand Mal Seizure Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Sanofi S.A.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. GlaxoSmithKline PLC
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Grand Mal Seizure Treatment Market Other Major And Innovative Companies

  • 31.1. Takeda Pharmaceuticals Inc.
  • 31.2. Mylan N.V.
  • 31.3. UCB Celltech Ltd.
  • 31.4. Sun Pharmaceutical Industries Ltd.
  • 31.5. Teva Pharmaceutical Industries Ltd.
  • 31.6. Aurobindo Pharma Limited
  • 31.7. Lupin Pharmaceuticals Inc.
  • 31.8. Dr. Reddy's Laboratories Ltd.
  • 31.9. Cipla Inc.
  • 31.10. Apotex Inc.
  • 31.11. Hikma Pharmaceuticals PLC
  • 31.12. Alkem Laboratories Ltd.
  • 31.13. Jubilant Life Sciences Limited
  • 31.14. Torrent Pharmaceuticals Ltd.
  • 31.15. Zydus Cadila

32. Global Grand Mal Seizure Treatment Market Competitive Benchmarking

33. Global Grand Mal Seizure Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Grand Mal Seizure Treatment Market

35. Grand Mal Seizure Treatment Market Future Outlook and Potential Analysis

  • 35.1 Grand Mal Seizure Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Grand Mal Seizure Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Grand Mal Seizure Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer